[A case of gastric cancer responding to TS-1, with long survival of 16 months].
We report the case of a 47-year-old woman with Stage VI gastric cancer accompanied by p2 grade dissemination which responded to chemotherapy using TS-1. Treatment of the patient with daily oral administration of 80 mg TS-1 for 2 cycles resulted in partial regression in the size of the primary lesion. Side effects were only seen after administration of 1 month, as mild pigmentation easily controlled by white vaseline ointment. After 6 cycles of administration, the effect on the gastric mucosal lesion decreased, and the wall thickness and stenosis of the antrum were increased. The patient has been administered 10 cycles of chemotherapy with no myelosupression, and maintains a good quality of life.
Sakata
Haruhito
H
Dept. of Surgery, Shioya General Hospital.
Uematsu
Takeshi
T
Mochizuki
Ryosuke
R
Ichinose
Masanori
M
Fukasawa
Kimiaki
K
Mukai
Minoru
M
Ochiai
Takenori
T
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D017640:Silicates / Q000008:administration & dosage / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014025:Titanium / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D017640:Silicates; C103828:titanium silicide; D014025:Titanium